Research and Markets: Remicade (infliximab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/gp466w/remicade) has announced the addition of the "Remicade (infliximab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.

The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Remicade (infliximab) was originally developed as a result of a collaboration between two professors at NYU Langone Medical Center and Centocor Ortho Biotech (acquired by Janssen Biotech, a subsidiary of J&J) (NYU Langone Medical Center, press release, August 12, 2005). It is first-generation TNF inhibitor consisting of a chimeric IgG1 mAb that is specific for TNFa. Remicade binds to TNFa with high affinity, neutralizing the effects of this cytokine, thus preventing synovial inflammation and decreasing joint erosion in patients with RA.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Remicade (infliximab) including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Remicade (infliximab) for the top 10 countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

3.3 Prognosis

3.4 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines

4.1.3 Leading Prescribed Drugs for the Treatment of RA

4.1.4 Clinical Practice

5 Competitive Assessment

6 Remicade (infliximab)

6.1 Overview

6.2 Efficacy

6.3 Safety

6.4 SWOT Analysis

6.5 Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/gp466w/remicade

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders